Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17528557 | 0.79 | BRD4 (0.37) | CRHR1EGFRPDGFRBKDR | |
| SCHEMBL17528586 | 0.74 | PDGFRB (0.41) | CRHR1EGFRPDGFRBKDR | |
| SCHEMBL19033752 | 0.74 | SYK (0.44) | EGFRPDGFRBKDRBTK | |
| SCHEMBL30426054 | 0.66 | NPSR1 (0.58) | EGFRPDGFRBKDRKCNN3ABL1 | |
| SCHEMBL19684529 | 0.66 | HRH4 (0.42) | KCNN3 | |
| SCHEMBL789756 | 0.65 | HRH4 (0.37) | KCNN3 | |
| SCHEMBL17528506 | 0.65 | KDR (0.59) | EGFRPDGFRBKDR | |
| SCHEMBL20558397 | 0.64 | BTK (0.55) | BTK | |
| SCHEMBL3113501 | 0.63 | MAPT (0.53) | CRHR1 | |
| SCHEMBL18711826 | 0.63 | HRH4 (0.36) | KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200369680-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-26 | — | — | US | disclosed |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-07 | — | — | US | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369680-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | CRHR1 2175/4885EGFR 1764/4885PDGFRB 997/4885 |
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | CRHR1 2230/4885EGFR 1662/4885PDGFRB 984/4885 |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | CRHR1 2458/4885EGFR 1982/4885PDGFRB 1337/4885 |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | CRHR1 2230/4885EGFR 1662/4885PDGFRB 984/4885 |
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | CRHR1 2175/4885EGFR 1764/4885PDGFRB 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.